Sulfadoxine and pyrimethamine (SP), commonly used for Plasmodium falciparum malaria treatment, interfere with the enzymes involved in the folate biosynthesis pathway of the parasite (8) . Point mutations in Plasmodium falciparum dihydrofolate reductase (PFDHFR) are known to give rise to pyrimethamine resistance. The first mutation occurs at the S108N codon, followed by C59R, N51I, and I164L mutations (8) . One could observe single, double, triple, or quadruple PFDHFR mutations depending on the level of drug resistance. P. falciparum isolates with increased numbers of PFDHFR mutations were found to show a higher degree of pyrimethamine resistance (8) . Indeed, the falciparum malaria patients containing quadruple PFDHFR mutations showed a treatment failure against this drug (8, 23) .
This antifolate drug also affects the Plasmodium vivax parasite since both contain the same target enzyme (7) . Pyrimethamine resistance in P. vivax is associated with two key DHFR mutations, S58R and S117N, which are equivalent to the C59R and S108N mutations of the PFDHFR (6) . In addition, other mutations (I13L, P33L, F57L/I, T61M, S117T, I172V, and I173L) in P. vivax DHFR (PVDHFR) have also been reported (4-7, 9-12, 14, 16, 18, 22) . Similar PVDHFR mutations at these codons except for I13L, P33L, I172V, and I173L have also been reported in India by various workers (11, 14, 22) .
The in vitro and in vivo data on PVDHFR mutations have now clearly established the association between pyrimethamine resistance and these mutations (9-11, 15, 20, 21) . For example, the wild-type PVDHFR enzyme expressed in Escherichia coli showed a higher catalytic activity than the mutant type enzyme (15, 20) . Similarly, wild-type and different mutant alleles of PVDHFR were expressed in Saccharomyces cerevisiae and tested for their susceptibilities to pyrimethamine (9, 10) . The yeast cells harboring the mutant PVDHFR constructs showed their survival at a higher concentration of pyrimethamine than those cells that were harboring the wild-type PVDHFR construct (9) . The degree of pyrimethamine resistance in P. vivax also increases with the sequential addition of each mutation in the dhfr gene, and extremely resistant parasites carry an S117T mutation (9, 10, 12) . Therefore, the PVDHFR allele with quadruple mutations (F57L plus S58R plus T61M plus S117T) exhibited the highest level of pyrimethamine resistance in the Saccharomyces cerevisiae system (9). The P. vivax malaria patients harboring this quadruple mutation were also unable to clear the parasite with pyrimethamine (21) . The DHFR mutations of both Plasmodium species have now been used as markers to assess antifolate drug pressure in the field (1-3, 5, 8, 10, 11, 14, 16, 18, 21-23) . Although DHFR mutations have been described separately for P. vivax and P. falciparum from various countries, there is no report showing DHFR mutations of both species together from the same region at a given time point, which can assess the cross-species effect of the antifolate treatment. Therefore, to asses the cross-species effect of antifolate usage, we decided to investigate the DHFR mutations among P. vivax and P. falciparum isolates from different parts of India, including those areas where we have recently reported the PFDHFR mutations (2). (Fig. 1) . Thick and thin blood smears of these patients were screened by light microscopy after Giemsa staining. Patients were treated with antimalarial drugs according to the National Drug Policy as described previously (2) . Briefly, the vivax malaria patients from Aligarh, Panna, Panjim, and Chennai were treated with a single dose of chloroquine (10 mg per kg body weight) followed by primaquine (0.25 mg per kg body weight) per day for 5 days. However, the P. vivax patients from Kamrup, Cuttack, and Car Nicobar were treated with a total dose of 1,500 mg chloroquine over a 3-day period (600 mg, 600 mg, and 300 mg for the first, second, and third days, respectively) along with the same dose of primaquine over a 5-day period. The P. falciparum malaria cases from these areas except Kamrup were treated with similar doses of chloroquine but a single dose of primaquine (0.75 mg per kg body weight). The P. falciparum malaria patients from Kamrup were treated with a single dose of sulfadoxine (25 mg per kg body weight) and pyrimethamine (1.25 mg per kg body weight). One hundred to 200 l of heparinized blood was collected from the malaria parasite-positive patients. Informed consent was obtained from the patients prior to blood collection according to institutional ethical guidelines. Previously, we used the P. falciparum-infected blood samples from UP, Assam, and A&N for the PFDHFR mutation studies (2). The remaining P. falciparum isolates from MP, Goa, and Orissa and the P. vivax-infected blood samples from all seven areas were used here for the DHFR mutation analysis.
MATERIALS AND METHODS

Parasite
Extraction of parasite DNA and PCR amplification of the dhfr gene. Parasite DNA was extracted from the blood of P. vivax and P. falciparum patients using an AccuPrep Genomic DNA extraction kit (Bioneer Corporation, Korea) according to the manufacturer's instructions. The DNA was eluted in Tris-EDTA buffer (pH 8.0), and an aliquot was used for the PCR amplification. A 1,014-bp fragment of the P. vivax dhfr-ts gene was amplified using primers PvDA (5Ј-AC CGCACCAGTTGATTCCTAC-3Ј) (forward) and PvDB (5Ј-TGTTAAAGCTG AAGTACACGAG-3Ј) (reverse) with the following cycling parameters: a 10-min initial denaturation step at 94°C was followed by 35 cycles with a 30-s denaturation step at 94°C, a 1-min annealing step at 58°C, a 1-min extension step at 72°C, and a final 10-min extension step at 72°C. This primary PCR product was diluted 10 times and used as a DNA template for nested PCR to amplify the 784-bp region, which covers the entire DHFR domain. Primers PvDF (5Ј-ATGGAGG ACCTTTCAGATGT-3Ј) (forward) and PvDR (5Ј-AACGCATTGCAGTTCTC CGA-3Ј) (reverse) were used for nested PCR with the following cycling parameters: a 10-min initial denaturation step at 94°C followed by 35 cycles with a 30-s denaturation step at 94°C, a 30-s annealing step at 54°C, a 1-min extension step at 72°C, and a final 10-min extension step at 72°C. Primers PvDA (covering Ϫ75 to Ϫ55 bp upstream to the pvdhfr-ts start codon), PvDB, PvDF, and PvDR were designed from the known pvdhfr-ts sequence of pyrimethamine-sensitive P. vivax isolate ARI/Pakistan (X98123). Amplification of the dhfr gene from P. falciparum isolates was carried out under the same conditions as those described previously (2) .
Nucleotide sequencing. An individual band of each PCR product was excised from the agarose gel and purified using an AccuPrep gel purification kit (Bioneer Corporation, Korea) according to the manufacturer's instructions. The entire pvdhfr gene was sequenced using primers PvDM (5Ј-GTTAGCGTCTTGGAA AGCAC-3Ј) and PvDR, while primers for the pfdhfr gene sequencing were same as those described previously (2) . Sequencing parameters and other downstream protocols were the same as those described previously (13) . The nucleotide sequences were translated into amino acids using the Edit sequence program (Lasergene, version 5.1, July 1999; DNASTAR Inc., Madison, WI). Amino acid sequences were aligned using the GeneDoc Multiple Sequence Alignment Editor and Shading Utility (version 2.6.002).
Statistical analysis. The chi-square test was applied to find significant differences between two groups. Furthermore, the chi-square test was also applied to assess the trends of DHFR mutations across the P. falciparum and P. vivax groups. A P value of Ͻ0.05 was considered significant.
RESULTS
Mutation analysis of the pvdhfr gene. We have sequenced the entire DHFR domain of the pvdhfr-ts gene from 177 P. vivax clinical isolates. Among these isolates, mutations were observed at F57L, S58R, T61M, S93H, S117N, and S117T Fig. 2A) . The mutation frequency at S58R and S117N was higher among the isolates. Seventy-six (42.94%; n ϭ 177) isolates contained the wild-type amino acids at these positions. Among the remaining isolates, the frequency of double DHFR mutations was highest, while no isolate was found to contain triple DHFR mutations (Fig. 2B) . The frequency of quadruple DHFR mutations was higher than the frequency of single and triple DHFR mutations. There were six different genotypes among these 177 isolates, where genotype F 57 R 58 T 61 S 93 N 117 was most prevalent, followed by L 57 R 58 M 61 S 93 T 117 (mutated amino acids are in boldface type) (Fig. 2C) .
Besides the nonsynonymous mutations, there was a synonymous mutation at codon 69 (TAT3TAC) coding for tyrosine. TAT at codon 69 was associated with all six different PVDHFR genotypes and was present in the majority of the isolates (85.88%; n ϭ 177). On the contrary, 24 of 25 isolates containing TAC at this codon were associated with the wild-type PVDHFR genotype.
There were variable numbers of GGDN repeats at amino acid position 88 of PVDHFR among the P. vivax isolates. The majority of them (91.53%; n ϭ 177) were found to contain three GGDN repeats, whereas the rest of them contained two (6.78%; n ϭ 177) or four (1.69%; n ϭ 177) repeats. While isolates with the wild-type PVDHFR genotype had a variable number of GGDN repeats, the majority of the isolates with mutated genotypes (98.02%; n ϭ 101) contained only three GGDN repeats.
Regional distribution of PVDHFR alleles. The majority of isolates from MP and UP contained the wild-type amino acids at the above-mentioned five codons of PVDHFR (Table 1) . On the contrary, the majority of isolates from Goa, Orissa, and TN were found to contain the double DHFR mutation genotype F 57 R 58 (Table 1) .
Thirteen different PVDHFR alleles were observed among the 177 P. vivax isolates when variations at three different loci were considered, i.e., nonsynonymous mutations together with a synonymous mutation (TAT3TAC) at codon 69 and GGDN repeats ( Table 2 ). The most common alleles had a TAT codon at 69 and three GGDN repeats associated with the F 57 R 58 T 61 S 93 N 117 (43.50%; n ϭ 177) or F 57 S 58 T 61 S 93 S 117 (22.60%; n ϭ 177) genotype. These two alleles (A1 and A11) were present in all the seven regions of the country. Certain alleles were rare and region specific, while others were present in more than one region ( Table 2) . Analysis of PFDHFR mutations. Previously, we described the PFDHFR mutations among 117 P. falciparum isolates from three regions of India (UP, Assam, and A&N) collected during 2003 and 2004 (2) . Here, we describe the PFDHFR mutations among 73 additional isolates collected from three other areas of the country (MP, Goa, and Orissa) during the same period (Table 3) . Isolates from all three additional areas showed a predominance of the double PFDHFR mutations (Table 3) , similar to the isolates from UP and Assam (2) . Quadruple PFDHFR mutations from A&N reported previously (2) were not observed in any of the isolates, while triple PFDHFR mutations were present in Orissa (Table 3) .
Relationship between PVDHFR and PFDHFR mutations. P. falciparum and P. vivax infections occur in all the seven study areas where we have analyzed the PVDHFR mutations (Table  1 ). We have already described PFDHFR mutations among 117 P. falciparum isolates from UP, Assam, and A&N (2), while the remaining 73 isolates from MP (n ϭ 24), Goa (n ϭ 22), and Orissa (n ϭ 27) were sequenced here (Table 3 ). Therefore, we were able to analyze the DHFR mutations of P. falciparum (190 isolates) and P. vivax (177 isolates) combined together from these areas, except TN. As shown in Fig. 3 and as confirmed by the chi-square test, there was a specific trend of DHFR mutations across the P. falciparum and P. vivax groups (P ϭ 0.0001). Nevertheless, the frequency of the wild-type PVDHFR genotype was significantly higher than that of the PFDHFR genotype (P ϭ 0.0001) among all the isolates combined together (Fig. 3) as well as in each region (Fig. 4) . The numbers of isolates containing double DHFR mutations for each species were higher than the numbers of isolates with single, triple, or quadruple DHFR mutations among all the isolates combined together (Fig. 3) as well as isolates of each region separately, except A&N, where quadruple DHFR mutations were predominant (Fig. 4) . Furthermore, the numbers of P. vivax isolates with double DHFR mutations were greater than those of P. falciparum (P ϭ 0.023) in A&N. Elsewhere, the frequencies of double DHFR mutations for both the species were almost same (P Ͼ 0.05), except for MP (P ϭ 0.001). Interestingly, the quadruple DHFR mutations were observed in P. vivax but not in P. falciparum isolates from Assam (Fig. 4) .
DISCUSSION
Antifolate drugs are commonly used for the treatment of falciparum malaria. According to the National Drug Policy of India, chloroquine-resistant uncomplicated falciparum malaria cases should be treated with SP. In those regions of India where chloroquine resistance has reached a very high level, SP is the first line of antimalarial drug, except for a few primary health centers, where artesunate-based combined therapy has recently been introduced as an alternative treatment. If P. falciparum and P. vivax species coexist in the region, both of them are at risk of being exposed to the antifolate drugs, as they have common target enzymes (7, 8) . We found here that the antifolate drug pyrimethamine was also affecting the P. vivax parasite, as PVDHFR mutations were observed among isolates of all seven regions (Table 1 ). This may be due to the fact that both of these species coexist together in these regions, a The PFDHFR mutations among P. falciparum isolates from UP, Assam, and A&N have been described in our previous studies (2) . The PFDHFR mutation data from three other regions (MP, Goa, and Orissa) are from this study.
b Mutated amino acids are shown in boldface type. and chloroquine-resistant falciparum malaria is treated with SP (17). Exposure of P. vivax to SP can occur in these areas for several reasons. First, there could be a situation where the clinician prescribes the antimalarial drug based on clinical grounds but lacks the opportunity of immediate diagnosis, and the inaccurate diagnosis of the parasite species also leads to a similar situation. Second, economic issues can also lead to the treatment of P. vivax malaria with SP because it is cost-effective, easily available, and simple to administer due to its singledose treatment regimen. Third, mixed P. falciparum and P. vivax infections may also be a reason for such a situation. Mixed infections are quite common in India despite the fact that there are separate transmission peaks for each species (19) . This may be due to the fact that there is a window period that overlaps between the peaks and provides a congenial environmental condition for the transmission of both the spe-cies. Indeed, 26% of our malaria-infected blood samples from
